Complications and mortality in ST-segment elevation acute myocardial infarction in diabetic and non-diabetic patients
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 8862-8866
AbstractBackground:Acute myocardial infarction (AMI) is one of the leading causes of all acute emergencies and is becoming an important public health problem in the developing countries. The present study was conducted to assess complications and mortality in ST-segment elevation acute myocardial infarction in diabetic and non-diabetic patients.
Materials & Methods: 80 consecutive patients of diabetic (group I) and non-diabetic (group II) having acute ST-segment elevation myocardial infarction (STEMI) of both genders were included. Different treatment was given to all patients.
Results: Age group <40 years had 12 diabetic and 14 non- diabetic, 40-55 years had 25 diabetic and 22 non- diabetic, 55-70 years had 15 diabetics and 18 non- diabetics and >70 years had 28 diabetics and 26 non- diabetics. The difference was non- significant (P> 0.05). Site of AMI was anterior in 30 and 20, inferior in 20 and 40, inferior+ right ventricular in 20 and 10 and lateral in 10 and 5 in group I and II respectively. Mortality was seen in those in which streptokinase was given in 6 and 3 and streptokinase not given in 14 and 8 in group I and group II respectively (P< 0.05). Type of treatment given was beta- blockers in 82, ACE inhibitors in 105, streptokinase in 96, aspirin in 154, statins in 128 and diuretics in 44 patients. The difference was significant (P< 0.05).
Conclusion: In diabetic and in non- diabetic, reduction in mortality rate was seen with the streptokinase administration. However, diabetics not on streptokinase had higher mortality as compared to non- diabetics
- Article View: 2
- PDF Download: 7